XORTX Therapeutics Advances Kidney Disease Program
Company Announcements

XORTX Therapeutics Advances Kidney Disease Program

Xortx Therapeutics (TSE:XRTX) has released an update.

XORTX Therapeutics Inc. made significant strides in 2023, achieving U.S. Orphan Drug Designation for its XRx-008 program for ADPKD and aligning with the FDA for accelerated approval pathways. The company successfully progressed through various stages, including drug substance production and clinical supply manufacturing, setting the stage for a pivotal registration clinical trial for their lead program XRx-008 in 2024. These developments mark a significant move towards marketing approval and shareholder value enhancement.

For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskXORTX Outlines Executive Compensation Strategy
TipRanks Auto-Generated NewsdeskXORTX Therapeutics Plans Major Warrant Repricing
TipRanks Auto-Generated NewsdeskXORTX Therapeutics Showcases Progress at BIO 2024
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!